Complete CSF biomarker profile for Alzheimer’s disease in the era of automation and standardization

Recording from the Educational Workshop #30 at EuroMedLab 2019.
"Add specialty to your routine: Reviewing a new Anti-Mullerian hormone assay and the first complete panel for fully automated biomarker testing in Alzheimer's disease"
Video 3: "A complete CSF biomarker profile for Alzheimer’s disease in the era of automation and standardization" presented by Dr. Daniel Alcolea
Fujirebio is a leader in providing in vitro diagnostics testing solutions, and a pioneer in automated chemiluminescence methods. This educational workshop will review newly developed assays in two different areas, namely the AMH (anti-Müllerian hormone) test within the fertility panel and a complete biomarker panel for Alzheimer’s disease biomarkers on the LUMIPULSE® G platform.
The Lumipulse G AMH assay was launched by Fujirebio Europe in the first half of 2019. The assay is based on a two-step sandwich immunoassay concept. The workshop will give detailed insight into the low range performance, which may be particularly interesting in prediction of ovarian reserve, time to menopause and may aid in the diagnosis and follow up of ovarian cancer.
Under the INNOTEST® brand name, Fujirebio pioneered in the field of neurodegenerative disease testing by commercializing the first in vitro diagnostic biomarkers for Alzheimer’s disease. The steadily growing acceptance of the clinical value of Alzheimer biomarkers, coupled with the expectation of new therapies, sets the stage for the fully automated processing of cerebrospinal fluid (CSF) samples. The Lumipulse G pTau 181 and β-Amyloid1-40 assays, launched in November 2018, are the latest additions to Fujirebio’s fully automated Alzheimer product line and complement the previously launched Lumipulse G Total Tau and β-Amyloid1-42 assays. These assays are intended to measure β-Amyloid1-42, β-Amyloid1-40, Total Tau and pTau 181 in CSF. Altogether, these four CSF markers support the diagnosis of Alzheimer’s disease, with the β-Amyloid1-42 / β-Amyloid1-40 ratio additionally being able to reduce the effect of inappropriate pre-analytics. The workshop will review the performance of Fujirebio’s Alzheimer biomarker panel available on the LUMIPULSE G automated analyzers.